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py with paclitaxel and carboplatin. Three years later, she developed
multiple lung metastases (maximum diameter: 20 mm) and subse-
quently underwent 6 cycles of paclitaxel and carboplatin,which resulted
in complete remission. However, she developed malignant ascites with
lungmetastases (maximum diameter: 10mm) and deep vein thrombo-
sis after 14 months. We initiated treatment using warfarin and she
underwent 2 cycles of carboplatin therapy, which induced anaphylaxis,
and then underwent 3 cycles of pegylated liposomal doxorubicin
(40 mg/m2), which induced interstitial pneumonia. Although the inter-
stitial pneumonia improved with prednisolone treatment, she subse-
quently presented with minor chest pain, a cough, and dyspnea in
February 2015 (Fig. 1).presentation, although computed tomography (CT) revealed lung me-1. Introduction
Pericardial effusion is an uncommon fatal complication of advanced
or recurrent ovarian cancer. Dauplat et al. reported that its incidence
was 2.4%, and all 6 patients in that series also had pleural effusion
(Dauplat et al., 1987). A PubMed search reveals 12 case reports of cardiac
tamponade thatwas associatedwith ovarian carcinoma, and themedian
overall survival (OS) among these cases was b2 months (Feferkorn
et al., 2014). In this report, we describe a patient with ovarian clear
cell carcinoma who ultimately developed pericardial and pleural effu-
sion, which were successfully managed using bevacizumab (Bev). To
our best knowledge, this is the ﬁrst report of using Bev to treat pericar-
dial effusion that was associated with ovarian cancer.
2. Case report
A 52-year-old nulliparous woman initially visited our hospital with
an ovarian tumor of 19 cm in diameter in 2010. After primary debulking
surgery, she was diagnosed with stage IC ovarian clear cell carcinoma
with positive cytology of ascites and the rupture of the left ovariand Gynecology, Hyogo College of
efecture 663-8501, Japan.
.
. This is an open access article underHer blood pressure and heart rate were normal at the February 2015
tastases (maximum diameter: 11 mm), minor right-side pleural effu-
sion, and pericardial effusion. Echocardiography revealed an echo-free
space of 20mmand diastolic collapse of the right atrium.Weperformed
pericardiocentesis, drained 700 mL of bloody ﬂuid, and performed cy-
tology, which revealed clear cell adenocarcinoma. The patient refused
combination chemotherapy with Bev due to the risk of gastrointestinal
perforation (GIP), and underwent 3 months of weekly treatment with
paclitaxel (wPTX, 80 mg/m2). Unfortunately, she developed a cough
and dyspnea due to the right-side pleural effusion, and refused hos-
pitalization for talc pleurodesis; therefore, we performed outpatient
thoracocentesis. The interval between thoracocentesis was reduced,
and she received an oral etoposide (50 mg daily). However, she re-
quired weekly thoracocentesis, and her dyspnea was exaggerated. Her
oxygen saturation was 82–86% in room air, with a blood pressure of
119/75 mm Hg and a heart rate of 124 bpm.
In May 2015, the patient was admitted to our emergency depart-
ment, where echocardiography revealed 25 mm of pericardial effusion
and diastolic collapse of the right atrium and ventricle. Her oxygen
saturation improved to 95%with an oxygenmask. As CT revealed pulmo-
nary embolism, despite her use of warfarin, we decided to place an infe-
rior vena cavaﬁlter, and administered heparin in addition to thewarfarin.
The patient exhibited bilateral pleural effusion and pericardial effusion
(Fig. 2), and her Eastern Cooperative Oncology Group performance status
(PS) was 3. Furthermore, she had mild ascites, underwent right-side
thoracocentesis, and 1450 mL of bloody pleural effusion was drained, al-
though her dyspnea and cough persisted. Her symptoms improved afterthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Treatment course for a patient with ovarian clear cell carcinoma (December 2014 to November 2015). PLD, pegylated liposomal doxorubicin at 40 mg/m2 every 28 days; wPTX,
weekly paclitaxel at 80 mg/m2; VP-16, 50 mg of oral etoposide daily; Bev, 15 mg/kg of bevacizumab; Bev + wPTX, 15 mg/kg of bevacizumab every 21 days and weekly paclitaxel at
80 mg/m2; PE, pulmonary embolization.
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she agreed to receive Bev therapy. After intravenous administration of
15 mg/kg of Bev, she was discharged. After 3 weeks, chest radiography
and echocardiography revealed no increase of pleural or pericardial effu-
sion, and her PS was improved to 1. She began a combination regimen of
Bev (15 mg/kg, triweekly) and wPTX (80 mg/m2). She has not required
pericardiocentesis or thoracocentesis for 18 weeks after the initiation of
Bev therapy.
3. Discussion
Malignant pericardial effusion or cardiac tamponade reduces pa-
tients' quality of life and can lead to a life-threatening condition. Approx-
imately one-half of these cases are comprised of patients with lung
cancer and breast cancer, and when malignant cells are detected in the
pericardial effusion, the patients' median OS is 7.3 months (Gornik
et al., 2005). This is consistent with the ﬁndings from the 12 cases of pa-
tients with ovarian cancer. In addition to repeated pericardiocentesis,Fig. 2. Computed tomography and echocardiography ﬁndings. (A) Computed tomography
(width: 32.9 mm). The patient underwent treatment with bevacizumab (15 mg/kg, every 21 dvarious treatments have been reported, such as surgical or percutaneous
balloon pericardiostomy, sclerotherapy, intrapericardial chemotherapy,
and radiation therapy (Gornik et al., 2005). In the present case, we
treated the patient using anticoagulation therapy for the pulmonary
embolism and deep vein thrombosis, whichwas likely due to the activa-
tion of her clear cell carcinoma (Matsuura et al., 2007). Unfortunately,
the surgical or invasive approach increases the risk of bleeding, and
sclerotherapy increases the risk of constrictive pericarditis, although
Petersen et al. have reported successfully treating a patientwith ovarian
cancer using intrapericardial administration of thiotepa (Petersen et al.,
2009). Chen et al. have recently reported intrapericardial administration
of Bev for a patientwith lung cancer and pericardial effusion (Chen et al.,
2015). Although most cases of malignant pericardial effusion or cardiac
tamponade with advanced or recurrent ovarian cancer exhibit pleural
effusion (Dauplat et al., 1987), local treatment appears to provide mini-
mal beneﬁt.
The etiology of pericardial effusion appears similar to that of malig-
nant effusion in the peritoneal and pleural cavities via metastases toreveals bilateral pleural effusion. (B) An echocardiogram reveals pericardial effusion
ays) after thoracocentesis and pericardiocentesis.
13T. Ueda et al. / Gynecologic Oncology Reports 16 (2016) 11–13the serosal membranes. Furthermore, vascular endothelial growth
factor (VEGF)-A is considered a keymolecule in the development ofma-
lignant ascites and pleural effusion. In this context, Bev is a human
monoclonal antibody to VEGF-A that preclinical and clinical studies
have demonstrated and is effective for controlling malignant ascites in
ovarian cancer, and pleural effusion in lung cancer (Pujade-Lauraine
et al., 2014; Bradshaw et al., 2013). At the last hospitalization in the
present case (May 2015), our patient complained of dyspnea and exhib-
ited tachycardia, hypoxia, pulmonary embolism, and pericardial and
pleural effusion. Anticoagulation therapy and placement of an inferior
vena cava ﬁlter for her acute pulmonary embolism, and drainage of
the pleural effusion via thoracocentesis, did not resolve her dyspnea.
However, drainage of the pericardial effusion and Bev monotherapy
improved her dyspnea and cough, which resulted in her discharge and
a sustained response for 3 weeks. She then underwent combination
therapy using Bev and wPTX, did not require pericardiocentesis or
thoracocentesis, and was not hospitalized for N4 months. Therefore,
we believe that the Bev therapy helped relieve her symptoms and im-
prove her quality of life during the late stage of ovarian cancer.
The patient in the present case was not classiﬁed as platinum-
resistant, although she had a history of anaphylaxis to platinum. She
experienced interstitial pneumonia that was induced by pegylated lipo-
somal doxorubicin, and did not respond towPTX and etoposide. The pa-
tient initially refused Bev therapy, as GIP is a known adverse effect of
this therapy. Cannistra et al. have reported that the incidence of GIP is
only 11.4% and that the number of previous regimens is a risk factor
(Cannistra et al., 2007). Furthermore, the AURELIA trial (a randomized
phase 3 trial) evaluated patients with platinum-resistant ovarian can-
cer, and reported that the incidence of GIP was only 2.2% among
Bev-treated patients, although that study excluded patients with a his-
tory of ≥3 previous regimens (Pujade-Lauraine et al., 2014). In contrast,
other reports have denied any relationship between the number of
previous regimens and the incidence of GIP.
When the patient eventually decided to accept Bev therapy, we
initially administered it as a monotherapy, as she had complained of
weakness. The patient was subsequently discharged, and received a
combination of Bev andwPTX in our outpatient clinic onceher condition
had improved. A recent retrospective study that compared Bev mono-
therapy and combination chemotherapy revealed that the combination
chemotherapy provided longer OS (hazard ratio: 0.51, p b 0.01) in the
multivariate analysis, with similar adverse events for both treatments
(Fuh et al., 2015). Furthermore, analysis according to chemotherapy inthe AURELIA trial revealed that wPTX and Bev were a promising combi-
nation. In the present case, the patient's cancer progressed after she had
received wPTX monotherapy, although it has remained stable during
the treatment using Bev and wPTX.
In conclusion, pericardial effusion or cardiac tamponade is a rare, but
fatal, complication of ovarian cancer. Furthermore, patients with peri-
cardial effusion can also experience pleural effusion. Given the poor
prognosis that is associated with malignant pericardial effusion, symp-
tom relief and cancer stabilization are the main goals of treatment,
and the efﬁcacy andmild toxicities of Bevmay indicate that it is a prom-
ising treatment.Disclosure
Written informed consent for this report was obtained from the
patient. The authors have no conﬂicts of interest to declare.References
Bradshaw, M., Mansﬁeld, A., Peikert, T., 2013. The role of vascular endothelial growth fac-
tor in the pathogenesis, diagnosis and treatment of malignant pleural effusion. Curr.
Oncol. Rep. 15, 207–216.
Cannistra, S.A., Matulonis, U.A., Penson, R.T., Hambleton, J., Dupont, J., Mackey, H., et al.,
2007. Phase II study of bevacizumab in patients with platinum-resistant ovarian
cancer or peritoneal serous cancer. J. Clin. Oncol. 25, 5180–5186.
Chen, D., Zhang, Y., Shi, F., Li, M., Zhu, H., Kong, L., Yu, J., 2015. Sustained response of
malignant pericardial effusion to intrapericardial bevacizumab in an advanced lung
cancer patient: a case report and literature review. Onco Targets Ther. 8, 2767–2770.
Dauplat, J., Hacker, N.F., Nieberg, R.K., Berek, J.S., Rose, T.P., Sagae, S., 1987. Distant metas-
tases in epithelial ovarian carcinoma. Cancer 60, 1561–1566.
Feferkorn, I., Shai, A., Gemer, O., Auslender, R., Lavie, O., 2014. The natural history of
pericardial tamponade secondary to recurrent ovarian carcinoma — a case report
and review of the literature. Gynecol. Oncol. Rep. 10, 53–55.
Fuh, K.C., Secord, A.A., Bevis, K.S., Huh,W., ElNaggar, A., Blansit, K., et al., 2015. Comparison
of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients.
Gynecol. Oncol. (Epub ahead of print).
Gornik, H.L., Gerhard-Herman, M., Beckman, J.A., 2005. Abnormal cytology predicts poor
prognosis in cancer patients with pericardial effusion. J. Clin. Oncol. 23, 5211–5216.
Matsuura, Y., Robertson, G., Marsden, D.E., Kim, S.N., Gebski, V., Hacker, N.F., 2007 Feb.
Thromboembolic complications in patients with clear cell carcinoma of the ovary.
Gynecol. Oncol. 104 (2), 406–410.
Petersen, E.E., Shamshirsaz, A.A., Brennan, T.M., Demetroulis, E.M., Goodheart, M.J., 2009.
Malignant pericardial effusion with cardiac tamponade in ovarian adenocarcinoma.
Arch. Gynecol. Obstet. 280, 675–678.
Pujade-Lauraine, E., Hilpert, F., Weber, B., Reuss, A., Poveda, A., Kristensen, G., et al., 2014.
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian
cancer: the AURELIA open-label randomized phase III trial. J. Clin. Oncol. 32,
1302–1308.
